Search results: (10000)
News Prediction of DM2 and CVD Development Risk Based on Lipidomic Risk Determination
The incidence of type 2 diabetes mellitus (DM2) and cardiovascular diseases (CVD) is strongly influenced by lifestyle and diet. Hypertension, hypercholesterolemia, and elevated blood glucose are often detectable before the full development of disease symptoms. Similarly, changes in the representation of other less noticeable markers—plasma lipids—can also be detected.
News What to add to amlodipine when it alone is not enough for hypertension?
Treating hypertension is a daily task for not only general practitioners and cardiologists. Polish doctors evaluated the effect of adding bisoprolol on the blood pressure of patients with inadequately controlled hypertension on amlodipine monotherapy in a placebo-controlled AMCOR study.
News Incidence of Brain Metastases and Intracranial Activity of Sotorasib in Patients with NSCLC with G12C Mutation of the KRAS Oncogene
Sotorasib is the first targeted drug approved for the treatment of metastatic non-small cell lung cancer (NSCLC) with the G12C mutation of the KRAS oncogene. The newly published study presented below investigated its intracranial activity.
News Administration of Fibrinogen Concentrate in Patients with Persistent Bleeding After Cardiac Surgery
Is the administration of fibrinogen concentrate in patients with persistent bleeding after initial cardiac surgery associated with an increased risk of thromboembolic events or death? Authors of a Swedish observational study published last year aimed to answer this question.
News Brentuximab Vedotin in Patients with R/R cHL in the Real World: What to Expect?
How does brentuximab vedotin (BV) perform as maintenance therapy in real-world practice for patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL) who have undergone autologous hematopoietic stem cell transplantation (HCT) and are at high risk of its failure? This question was posed by authors from King Abdullah International Medical Research Center at King Saud bin Abdulaziz University for Health Sciences in Riyadh. They presented their findings in a poster session at this year's virtual European Society for Blood and Marrow Transplantation (EBMT 2022) congress.
News Alleviation of Asthma and Chronic Sinusitis Symptoms in Patients with Atopic Dermatitis Thanks to Dupilumab
An analysis of results in adult patients with moderate to severe atopic dermatitis, who also had asthma and/or chronic rhinosinusitis, investigated how clinically and statistically significant the benefit of dupilumab is for all these 3 conditions in comparison with a placebo.
News Programmed Cell Death as a Therapeutic Target in Chronic Lymphocytic Leukemia
One of the key steps in malignant transformation is the disruption of apoptosis. Tumor cells exploit a variety of mechanisms that allow them to evade programmed cell death. Among the drugs targeting apoptosis pathway regulators is venetoclax, a Bcl-2 protein inhibitor used in the treatment of chronic lymphocytic leukemia (CLL). Since August 2021, venetoclax in combination with obinutuzumab can newly be used as a reimbursed therapy for previously untreated patients with CLL who are not suitable for fludarabine administration.
News DPP4 Inhibitors in Chronic Kidney Disease and Their Potential to Protect Against Diabetic Nephropathy
Preclinical and clinical observations suggest that dipeptidyl peptidase 4 (DPP4) inhibitors might offer additional benefits to patients apart from effective and safe glycemic control.
News Impact of Chronic Urticaria on Patients' Quality of Life and Society
An international team of dermatologists has mapped out the impact of chronic urticaria on various aspects of patients' lives and the economic burden this long-term disease, without available causal treatment, represents for society, according to available literature.
News Cardiovascular Safety of Tofacitinib in Real-World Clinical Practice – Results of the STAR-RA Study
Recent results from the ORAL Surveillance clinical trial have raised concerns about the cardiovascular adverse effects of tofacitinib in patients with rheumatoid arthritis. A comprehensive analysis of real-world clinical practice data, involving nearly 13,000 patients, focused on the cardiovascular safety of tofacitinib for this indication.
News Adherence to Treatment of Multiple Sclerosis: How to Enhance It and What Interesting Insights Emerged from Current Research?
Therapeutic options for patients with multiple sclerosis (MS) utilizing disease-modifying drugs (DMDs) have continued to expand in recent years. However, achieving their full benefit is critically dependent on adherence to treatment. Nonadherence is demonstrably linked to an increased risk of relapses, faster progression of disability, higher treatment costs, and higher mortality. We present a summary of factors affecting adherence to treatment in MS patients, including the influence of the chosen therapy from a 2022 review and subsequent studies.
News ESC 2022: SGLT2 Inhibitors as Hope for HFpEF: How to Implement Them in Practice?
Patients with heart failure (HF) can significantly benefit from the inclusion of sodium-glucose co-transporter 2 inhibitors (SGLT2i, i.e., gliflozins) in their treatment strategy according to current findings. This also applies to patients with preserved left ventricular ejection fraction (HFpEF). At the ESC 2022 congress, useful information for practical applications was presented in addition to study data. For illustration, we bring a case study from a German practice.
News Reducing Cardiovascular Risk in Diabetics Through Hypertension Treatment
The presence of hypertension in patients with diabetes worsens overall cardiovascular (CV) prognosis and increases the prevalence of chronic renal failure. Adequate treatment of hypertension can significantly influence the development and severity of these complications. What target blood pressure (BP) values should we aim for in diabetics, which antihypertensive therapy to choose, and why not forget about 24-hour BP monitoring?
News Efficacy and Safety of Dual Bronchodilator Therapy for COPD – From Randomized Clinical Trials to Real-World Clinical Practice
Dual bronchodilator therapy (LAMA + LABA) represents one of the mainstays of treating chronic obstructive pulmonary disease (COPD). The aim of the recent systematic review presented below was to assess the efficacy and safety of this dual therapy compared to monotherapy or other combinations in the context of clinical trials and real-world clinical practice.
News Quo vadis, erdostein? Or the current and future potential of erdosteine in practice
Erdosteine has a well-established place in the therapy of acute respiratory diseases in children. Its mucolytic and antibacterial properties are very well documented. Recently, research has focused primarily on the anti-inflammatory and antioxidant effects of this molecule. Attention is also being paid to its antiviral potential. How does it stand in this regard?
News Frequent Nausea During Chemotherapy Despite Antiemetic Prophylaxis
Current clinical research has focused on vomiting as a primary issue in the occurrence of CINV (chemotherapy-induced nausea and vomiting) and, using recommended antiemetic prophylaxis, this problem has been relatively well managed. However, the incidence and impact of nausea are underreported. We present the results of an observational study that evaluated the incidence of nausea in patients undergoing chemotherapy.
News Effect of Initiation of Warfarin Therapy on the Risk of Ischemic Stroke
Anticoagulant therapy is essential in patients with atrial fibrillation for the prevention of thromboembolic events. Warfarin is a highly effective anticoagulant, but the introduction of new oral anticoagulants (NOACs) has offered certain advantages over it. Shortly after starting warfarin therapy, patients have repeatedly been shown to have a paradoxically increased risk of developing ischemic stroke. The aim of the study presented below was to determine whether this increase in risk is associated with the initiation of anticoagulant therapy.
News Can Antihypertensives Reduce the Risk of Dementia? The Answer Suggests the Angiotensin Hypothesis and a Post-Hoc Analysis of an Observational Study
The use of antihypertensives that do not reduce angiotensin II levels, such as angiotensin receptor blockers (ARBs, i.e., sartans) and calcium channel blockers (CCBs), has been associated with a lower risk of dementia in studies. In the research cited below, the authors aimed to determine whether this effect persists longer than the follow-up period in previous studies.
News Bilastine in the treatment of allergic rhinitis – meta-analysis shows advantage of lower somnolence
A newly published systematic review and meta-analysis evaluate the efficacy and safety of bilastine in the treatment of allergic rhinitis (AR), which includes symptoms of common rhinitis and allergic sensitization upon allergen exposure. The disease causes significant discomfort for patients and reduces their quality of life, which is why its control is essential for their daily functioning.
News Can alpha-1-antitrypsin deficiency affect severity and higher mortality in COVID-19 patients?
Alpha-1-antitrypsin (AAT) deficiency is commonly found in the European population. The most cases are recorded in countries with the highest COVID-19 mortality rates. Are there direct correlations?
News Teriflunomide vs. Dimethyl Fumarate in Real Practice: We Know the Winner! Will It Surprise You?
Teriflunomide and dimethyl fumarate are disease-modifying drugs (DMDs) used in the treatment of multiple sclerosis (MS). Regarding the course, form, and severity of MS, their target groups are comparable in their characteristics. These DMDs are therefore ideal candidates for mutual comparison. Swedish authors decided to compare their effectiveness based on data from real clinical practice obtained through the Swedish National Registry.
News Asthma is not a risk factor for a severe course of COVID-19
According to the statement of the Czech Initiative for Asthma from April 2020, the disease COVID-19 caused by the new type of coronavirus does not pose significantly greater danger for people with asthma than for the general population. It is, however, necessary to adhere to the prescribed treatment and keep asthma under control. The Journal of Allergy and Clinical Immunology provides an explanation for this surprising phenomenon. It is the reduced expression of ACE2 receptors in people with asthma and allergies, as shown by a new study involving three cohorts of pediatric and adult patients. The SARS-CoV-2 virus uses ACE2 receptors to enter the host cell.